Koh, Siang-Boon <br/><br/>
Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.  [electronic resource] 

 -  Cancer research  06 2018 
 - 3054-3066 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-17-3932  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Cycle Proteins--antagonists & inhibitors<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Checkpoint Kinase 1--antagonists & inhibitors<br/>DNA Damage--drug effects<br/>DNA Replication--drug effects<br/>Deoxycytidine--analogs & derivatives<br/>Drug Synergism<br/>Female<br/>Humans<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Nuclear Proteins--antagonists & inhibitors<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays--methods<br/>Gemcitabine